In the spirit of the holiday season, I would like everyone to repeat this stat a few times out loud: “Estimated holiday sales for 2019 are expected to be roughly $143 billion,” according to Adobe Analytics.
It’s Black Friday and let the holiday shopping games begin! American shoppers are expected to spend an average of $1,048 during the 2019 holiday shopping season. And how will they pay for it?
As a thematic investor, my job is to identify the most important and prevalent trends here and around the world to invest in through the leaders or “brands” that are most relevant. When I look at the world currently and into the future, here’s the most important investment themes an investor can invest in today.
Growth companies have been significantly outperforming value companies since early 2007 with just a few periods of value relative performance. There are many reasons for this, one of which is the simple concept that when something is scarce — economic growth and corporate growth — people are willing to pay up for it.
Interest rates have gone from 3% on the 10-year Treasury to roughly 1.5% at the lows last month. In addition, mortgage rates have gone from 5.2% last November to as low as 3.4% in late September. The big question is what happens when rates go lower, particularly in an economy out of recession more often than not?
When I got into this business in 1993, the idea that a public company could be worth more than $1 trillion was not even a consideration. In the history of public markets leading up to that time, the prevailing feeling was that since it never happened before, why should it happen in the future?
MGM Growth Properties LLC (MGP) is a growth-oriented REIT formed in 2015. The entity engages in the acquisition, ownership and leasing of large-scale destination entertainment and leisure resorts, whose amenities include casino gaming, hotel, convention, dining, entertainment and retail offerings.
Founded in 2002, Reata Pharmaceuticals is an Irving, Texas-based biopharmaceutical company. The late clinical stage company focuses on small-molecule therapeutics by targeting molecular pathways that regulate cellular metabolism and inflammation.
The discretionary sector struggled as did all growth and quality-oriented areas of the market in 2022. That was a classic re-set and a raging opportunity to add exposure.
The Institute for Supply Management’s monthly survey of purchasing managers came in below expectations for August, while the Bureau of Labor Statistics jobs report indicated that nonfarm payrolls expanded by only 142,000 jobs during the month (against expectations of 161,000 jobs).
Catalyst Funds
Rational Funds
Strategy Shares